Editor's PickMarket News

Zynerba Pharmaceuticals showcases Zygel study poster at annual SLEEP meeting

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) unveiled a poster highlighting sleep data from a study of its Zygel transdermal cannabinoid therapy at the Associated Professional Sleep Societies, SLEEP 2021 Annual meeting. This year’s SLEEP meeting is being held virtually and runs from June 10 through June 13. Zynerba’s study was conducted on children and adolescents with both developmental and epileptic encephalopathies (DEE) and autism spectrum disorder (ASD). READ: Zynerba says it’s fully funded well into 2024; lays out plans for Zygel RECONNECT trial for Fragile X patients According to the poster, an open-label phase II trial on patients with DEE found that treatment with Zygel was associated with improved sleep in children with clinically significant sleep disorders at baseline. The study also denoted that the children with both DEE and ASD showed more wide-ranging benefits compared to those with DEE alone. “Epilepsy and sleep disorders have a bidirectional relationship and co-occur in individuals with ASD. Improvements in sleep may result in better seizure control and behavior in these medically fragile children with DEE,” Joseph M. Palumbo, chief medical officer of Zynerba, said in the statement. He continued: “While these results are exploratory in nature, they are encouraging and warrant confirmation in future clinical trials of Zygel in patients with DEE and/or ASD.” The release went on to state, the test group of patients with DEEs aged 3 – 17 recorded improvements in various aspects.  While registrants with ASD also experienced improvements compared to baseline in sleep breathing, sleep wake transition and the total sleep disturbance scale for children over the 26-week study period. Additionally, most of the treatment-emergent adverse events were characterized as mild or moderate. Zynerba Pharmaceuticals continues to be a leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. Contact the writer at georgia@proactiveinvestors.com Follow her on Twitter @MissInformd

Leave a Reply

Your email address will not be published. Required fields are marked *